Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | BCR | P11274 | 3/20 | 0.53 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9491355 | 0.91 | SIGMAR1 (0.63) | SIGMAR1ABL1BCRL3MBTL1LMNA | |
| SCHEMBL25040036 | 0.86 | KDM4E (0.54) | SIGMAR1EPHX2LMNAKMT2AMEN1 | |
| SCHEMBL13841388 | 0.83 | TSHR (0.60) | L3MBTL1LMNAKMT2AMEN1KDM4E | |
| SCHEMBL8245365 | 0.81 | KMT2A (0.65) | SIGMAR1EPHX2LMNAKMT2AMEN1 | |
| SCHEMBL25039506 | 0.81 | ICMT (0.42) | SIGMAR1ABL1BCRLMNAKMT2A | |
| SCHEMBL11916145 | 0.80 | ABL1 (0.52) | SIGMAR1ABL1BCREPHX2L3MBTL1 | |
| SCHEMBL15315541 | 0.80 | RAB9A (0.47) | SIGMAR1ABL1BCRL3MBTL1LMNA | |
| SCHEMBL13547569 | 0.80 | TRPC5 (0.49) | SIGMAR1ABL1BCRLMNAKMT2A | |
| SCHEMBL2054619 | 0.80 | SMN1; SMN2 (0.71) | EPHX2LMNAKMT2AMEN1CD274 | |
| SCHEMBL3222264 | 0.80 | CD274 (0.55) | ABL1BCRL3MBTL1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023016447-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| US-7842708-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022506-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | TFPI, F11, F12 | SIGMAR1 4411/4885ABL1 467/4885BCR 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.